Home/Publication/Qiming & OrbiMed Join Morningside in Gene Therapy
Qiming & OrbiMed Join Morningside in Gene Therapy 

31 Aug 2023

US$ 19.00

Qiming Venture Partners and OrbiMed Advisor LLC have co-led the US$32 million series A funding round of Epigenic...

Price / article: US$19.00
OR existing subscriber
Related Publications

Listen to Japan/South Korea Funds (Subscribers' Weekly 09 Jan 2026)...

Subscribers’ Weekly for the week ending 9 Jan 2026...

Connect With Us

We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.

Rest assured that your email address will not be shared, as we hate spams as much as you do.